Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib plus third-generation EGFR-TKI in EGFR exon 21 L858R-mutated NSCLC (Phase IIa)
ChiCTR2600122473Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122473.